The primary goal of this acute, inpatient treatment protocol is to compare the putative, short-term benefit of the most selective and highly potent serotonin reuptake inhibitor (citalopram) and our usual pharmacotherapy (perphenazine) with placebo in reducing behavioral disturbances and/or psychosis associated with dementia. In addition, precise drug metabolic probes are used to identify those at risk of adverse psychotropic side effects.
Showing the most recent 10 out of 859 publications